---
title: "Jacobio Pharma files HKEX next-day disclosure return on share repurchase at HKD 5.08 each"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293608764.md"
description: "Jacobio Pharmaceuticals filed a next-day disclosure with the HKEX regarding a share repurchase on July 23. The company bought back 97,800 shares at prices ranging from HKD 5.03 to HKD 5.12 per share, totaling HKD 497,268. These shares were held as treasury shares and are designated for cancellation."
datetime: "2026-07-23T11:36:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293608764.md)
  - [en](https://longbridge.com/en/news/293608764.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293608764.md)
---

# Jacobio Pharma files HKEX next-day disclosure return on share repurchase at HKD 5.08 each

-   Jacobio Pharmaceuticals filed a next-day disclosure return showing a July 23 repurchase of 97,800 shares, held as treasury shares. \* Buyback executed on-exchange at HKD 5.03 to HKD 5.12 per share; total consideration HKD 497,268. \* Shares repurchased for cancellation: 0. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254581), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01167.HK](https://longbridge.com/en/quote/01167.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Jacobio doses first patient in Phase IIa China trial of JAB-8263 for rheumatoid arthritis](https://longbridge.com/en/news/293854649.md)
- [Ascendia Pharmaceutical Solutions attends Contract Pharma Conference](https://longbridge.com/en/news/295588895.md)
- [Lyophilisation is growing in pharma, but technical challenges persist](https://longbridge.com/en/news/295508023.md)
- [Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss?](https://longbridge.com/en/news/295294827.md)
- [ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance](https://longbridge.com/en/news/295227182.md)